JNJ

238.92

-0.45%↓

UNH

276.74

+0.12%↑

TMO

547.98

+1.1%↑

ABT

110.77

-0.05%↓

ISRG

492.64

+1.1%↑

JNJ

238.92

-0.45%↓

UNH

276.74

+0.12%↑

TMO

547.98

+1.1%↑

ABT

110.77

-0.05%↓

ISRG

492.64

+1.1%↑

JNJ

238.92

-0.45%↓

UNH

276.74

+0.12%↑

TMO

547.98

+1.1%↑

ABT

110.77

-0.05%↓

ISRG

492.64

+1.1%↑

JNJ

238.92

-0.45%↓

UNH

276.74

+0.12%↑

TMO

547.98

+1.1%↑

ABT

110.77

-0.05%↓

ISRG

492.64

+1.1%↑

JNJ

238.92

-0.45%↓

UNH

276.74

+0.12%↑

TMO

547.98

+1.1%↑

ABT

110.77

-0.05%↓

ISRG

492.64

+1.1%↑

Home・Aandelen Lijst・Avita Therapeutics Inc

Avita Therapeutics Inc

Open

4.05 4.11

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.73

Max

4.06

Belangrijke statistieken
By Trading Economics
Inkomsten	-3.3M -13M
Verkoop	-1.4M 17M
Winstmarge	-77.289
Werknemers	260
EBITDA	-3.2M -11M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+15.38% upside

Dividenden
By Dow Jones
Volgende Winsten	12 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	8.2M 129M
Vorige openingsprijs	-0.06
Vorige sluitingsprijs	4.05

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

8.83 / 9.77 Steun & Weerstand

Avita Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 feb 2026, 23:57 UTC

Marktinformatie

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8 feb 2026, 23:47 UTC

Marktinformatie

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8 feb 2026, 23:43 UTC

Marktinformatie

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8 feb 2026, 23:34 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 feb 2026, 23:34 UTC

Marktinformatie

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8 feb 2026, 23:26 UTC

Marktinformatie

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8 feb 2026, 21:43 UTC

Marktinformatie

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8 feb 2026, 21:16 UTC

Marktinformatie

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8 feb 2026, 21:15 UTC

Marktinformatie

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7 feb 2026, 09:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

7 feb 2026, 09:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 feb 2026, 05:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

7 feb 2026, 02:46 UTC

Acquisities, Fusies, Overnames

Big Money, High Anxiety -- Barrons.com

6 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

6 feb 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

6 feb 2026, 21:40 UTC

Acquisities, Fusies, Overnames

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 feb 2026, 21:22 UTC

Marktinformatie

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 feb 2026, 21:17 UTC

Winsten

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 21:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

6 feb 2026, 21:14 UTC

Acquisities, Fusies, Overnames

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 feb 2026, 21:13 UTC

Winsten

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 feb 2026, 21:13 UTC

Winsten

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 feb 2026, 21:04 UTC

Marktinformatie

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 feb 2026, 20:34 UTC

Winsten

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Peer Vergelijking

Prijswijziging

Avita Therapeutics Inc Prognose

Koersdoel

By TipRanks

15.38% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.5 USD 15.38%

Hoogste 5.5 USD

Laagste 3.5 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avita Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Avita Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.83 / 9.77Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.